Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

医学 血管舒缩 更年期 安慰剂 临床试验 随机对照试验 物理疗法 内科学 替代医学 病理
作者
Samuel N. Lederman,Faith D. Ottery,Antonio Cano,Nanette F. Santoro,Marla Shapiro C.M.,Petra Stute,Rebecca C. Thurston,Marci English,Catherine Franklin,Misun Lee,Genevieve Scott Neal-Perry
出处
期刊:The Lancet [Elsevier BV]
卷期号:401 (10382): 1091-1102 被引量:302
标识
DOI:10.1016/s0140-6736(23)00085-5
摘要

Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in menopausal women as options are scarce for those who cannot or do not want to take hormone therapy. Fezolinetant is one of the first non-hormonal neurokinin 3 receptor antagonists in development for the treatment of vasomotor symptoms due to menopause. This study investigated the safety and efficacy of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.SKYLIGHT 1 is a randomised, double-blind, placebo-controlled, 12-week, phase 3 trial with a 40-week active treatment extension. This trial was done at 97 facilities across the USA, Canada, Czech Republic, Hungary, Poland, Spain, and the UK. Women aged 40-65 years with an average of seven or more moderate-to-severe hot flashes per day were randomly assigned (1:1:1) to once-daily exact-matched placebo, fezolinetant 30 mg, or fezolinetant 45 mg. Randomisation was done using a web-based interactive response system and investigators, project team members, clinical staff, and participants were masked to treatment assignment. Coprimary endpoints were mean change in frequency and severity of vasomotor symptoms from baseline to weeks 4 and 12. The efficacy and safety analyses comprised all randomly assigned participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT04003155) and is completed.Between July 11, 2019, and Aug 11, 2021, 2205 women were recruited of whom 175 were assigned to placebo, 176 to fezolinetant 30 mg, and 176 to fezolinetant 45 mg (175 in the placebo group, 174 in the fezolinetant 30 mg group, and 173 in the fezolinetant 45 mg received at least one dose [safety analysis set]). One participant randomly assigned to fezolinetant 45 mg received fezolinetant 30 mg in error, so the efficacy analysis set (full analysis set) consisted of 173 in the fezolinetant 30 mg group and 174 in the fezolinetant 45 mg group. 23 participants in the placebo group, 31 in the fezolinetant 30 mg group, and 13 in the fezolinetant 45 mg group discontinued treatment before week 12, mostly due to adverse events or participant withdrawal. Compared with placebo, fezolinetant 30 mg and fezolinetant 45 mg significantly reduced the frequency of vasomotor symptoms at week 4 (difference in change in least squares mean -1·87 [SE 0·42; p<0·001], -2·07 [SE 0·42; p<0·001]) and week 12 (-2·39 [SE 0·44; p<0·001], -2·55 [SE 0·43; p<0·001]). Compared with placebo, fezolinetant 30 mg and 45 mg significantly reduced the severity of vasomotor symptoms at week 4 (-0·15 [0·06; p=0·012], -0·19 [0·06; p=0·002]) and week 12 (-0·24 [0·08; p=0·002], -0·20 [0·08; p=0·007]). Improvements in frequency and severity of vasomotor symptoms were observed after 1 week and maintained over 52 weeks. During the first 12 weeks, treatment-emergent adverse events occurred in 65 (37%) of 174 women in the fezolinetant 30 mg group, 75 (43%) of 173 in the fezolinetant 45 mg group, and 78 (45%) of 175 in the placebo group. The incidence of liver enzyme elevations was low (placebo n=1; fezolinetant 30 mg n=2; fezolinetant 45 mg n=0) and these events were generally asymptomatic, transient, and resolved while on treatment or after treatment discontinuation.Data support the clinical use of fezolinetant as a non-hormonal treatment for vasomotor symptoms associated with menopause. The study was placebo-controlled for 12 weeks followed by a 40-week blinded extension to assess the maintenance of effect. Furthermore, the population studied was diverse and representative of the potential target population for fezolinetant therapy. Further characterisation of the benefit of fezolinetant on quality of life, including on symptoms of mood and sexual wellbeing, merits investigation.Astellas Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
拼搏翠安完成签到 ,获得积分10
刚刚
zhu发布了新的文献求助10
刚刚
czm完成签到,获得积分10
刚刚
墨染星辰完成签到,获得积分10
刚刚
小碗菌完成签到,获得积分10
刚刚
崎路人完成签到,获得积分10
刚刚
ding的应助被张晨宸采纳,获得10
1秒前
李健的应助被霸气小兔子采纳,获得30
1秒前
LX完成签到,获得积分10
1秒前
1秒前
1秒前
酷炫的忆山完成签到,获得积分10
2秒前
fung发布了新的文献求助10
2秒前
Owen的应助被mc采纳,获得10
2秒前
HiJ发布了新的文献求助10
3秒前
HiJ发布了新的文献求助10
3秒前
桃也雾漫漫完成签到 ,获得积分10
3秒前
袁123发布了新的文献求助10
3秒前
3秒前
风中的南晴完成签到,获得积分10
3秒前
3秒前
3秒前
4秒前
且行发布了新的文献求助10
4秒前
stone发布了新的文献求助10
4秒前
5秒前
5秒前
英俊的铭的应助被孙大伟采纳,获得10
5秒前
清秀凌蝶发布了新的文献求助10
5秒前
夏目完成签到,获得积分10
6秒前
HiJ发布了新的文献求助10
6秒前
某幻想家完成签到,获得积分10
6秒前
lzt111完成签到,获得积分10
6秒前
clihye完成签到,获得积分10
7秒前
chi完成签到,获得积分10
7秒前
7秒前
李健的应助被12121采纳,获得10
7秒前
多是一杯美式完成签到 ,获得积分10
8秒前
不爱吃番茄完成签到,获得积分10
9秒前
高挑的金毛完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315